Adjunctive Soticlestat in Pediatric and Young Adult Dravet Syndrome

Randomised, double-blind trial in Dravet syndrome comparing Soticlestat with Placebo (2 arms). Primary endpoints: Percent change from baseline in convulsive seizure frequency per 28 days during the Full Treatment Period and Percent change from baseline in convulsive seizure frequency per 28 days during the Maintenance Period. Started Oct 2021; status: completed.